Exit surveys and interviews from RECONNECT trials confirmed bremelanotide-treated premenopausal women with HSDD experienced increased sexual desire and physical arousal that placebo-treated women did not, validating the clinical trial primary findings from the patient perspective.
Real physiological effectsWomen on bremelanotide reported physical arousal and desire that placebo-treated women did not — confirming the drug produces genuine physiological changes beyond placebo expectations
What the researchers found
From 242 exit surveys and 80 telephone interviews, bremelanotide-treated women described increased sexual desire, physical arousal, and improved sexual activity quality — physiological responses not reported by placebo-treated women, who described non-physiological benefits only.
Why it matters
HSDD significantly impacts women's quality of life and relationships. Patient-reported outcomes confirming real physiological improvements — beyond placebo effects — validate bremelanotide as a genuine treatment, not just a psychological intervention.
The numbers in context
242 exit surveys; 80 phone interviews; bremelanotide users reported desire, arousal, relationship quality improvements; placebo users reported communication benefits only
How the study worked
Post-trial qualitative study from RECONNECT Phase 3 trials (NCT02333071, NCT02338960). 242 quantitative exit surveys (17 questions) and 80 qualitative telephone interviews (17 questions). Participants blinded to treatment assignment during assessment.
Who was studied
Premenopausal women with hypoactive sexual desire disorder from RECONNECT trials
What this study cannot tell us
Post-hoc qualitative analysis from a clinical trial population. Self-reported outcomes subject to recall and reporting bias. Limited to premenopausal women. Only 80 completed interviews. Cultural factors may influence reporting.
How to read the evidence
Moderate evidence: large qualitative dataset (242 surveys, 80 interviews) from blinded Phase 3 trial participants. Confirms primary trial findings from patient perspective.
When this study was published
Published 2021. Bremelanotide (Vyleesi) was approved in 2019 and is commercially available.
The bigger picture
Sexual health pharmacotherapy has been controversial, with debates about whether treatments provide genuine physiological benefits or just placebo effects. This patient perspective data clearly separates bremelanotide's physiological effects from placebo's psychological ones.
Questions still open
- How do bremelanotide's subjective effects compare between different doses?
- Do the patient-reported benefits persist with long-term use?
- Would similar patient perspective assessments be valuable for other sexual health treatments?
Common questions
What does bremelanotide (Vyleesi) actually feel like?
Is bremelanotide better than placebo?
Read the original research
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Journal of women's health (2002), 30(4), 587-595
Citation
Koochaki, Patricia; Revicki, Dennis; Wilson, Hilary; Pokrzywinski, Robin; Jordan, Robert; Lucas, Johna; Williams, Laura A; Sadiq, Amama; Krop, Julie. (2021). The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.. Journal of women's health (2002), 30(4), 587-595. https://doi.org/10.1089/jwh.2020.8460